BRAF mutation and neoadjuvant chemo-immunotherapy, is it worthwhile?
Saved in:
| Title: | BRAF mutation and neoadjuvant chemo-immunotherapy, is it worthwhile? |
|---|---|
| Authors: | Gallina FT; Thoracic Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy; Tumor Immunology and Immunotherapy Unit, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy. Electronic address: filippo.gallina@ifo.it., Cecere FL; Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Bergomi S; Division of Nuclear Medicine, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Buglioni S; Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Visca P; Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Landi L; Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Cappuzzo F; Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy. |
| Source: | Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2025 May; Vol. 203, pp. 108514. Date of Electronic Publication: 2025 Apr 03. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
